BG-60366 / BeOne Medicines - LARVOL DELTA

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Update (Businesswire) - "Anticipate...internal proof-of-concept data for BG-60366 (EGFR CDAC), BGB-53038 (panKRAS inhibitor), BG-C137 (FGFR2b ADC), BGB-C354 (B7H3 ADC), and BG-C477 (CEA ADC) in the second half of 2025."

P1 data • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BG-60366-101: A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=93 | Recruiting | Sponsor: BeiGene | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=93 | Not yet recruiting | Sponsor: BeiGene

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor